Der Quotient zeigt damit an, wie viel Kapazitt zur antioxidativen Reaktion aktuell im System verfgbar ist
0.9% benzyl acid, excipient qs 30 ml
At a glance Interaction type / pharmacokinetic (CYP3A4 inhibition) plus pharmacodynamic (additive BP lowering) Enzyme involved / CYP3A4 (primary route of amlodipine metabolism) Resveratrol dose linked to CYP inhibition / as low as 500 mg/day in human PK studies Amlodipine half-life / 30 to 50 hours, so enzyme inhibition effects accumulate slowly Main clinical risk / symptomatic hypotension, reflex tachycardia, worsened pedal edema Estrogenic concern / resveratrol binds estrogen receptor alpha
doi: 10.1111/1751-7915.13759 47 DeriuE.LiuJ
The varied success of anti-inflammatory agents suggests that targeting specific inflammatory pathways (like IL-1 or IL-6) or using agents with broad but relevant mechanisms (like colchicine affecting inflammasomes and neutrophil function) may be more effective than general immunosuppression (methotrexate) or targeting single enzymes (darapladib)
Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD